Simulated transmission settings.

<p>Legend: a (dashed purple line): EIR = 11 ibpa; b (dashed black line): EIR = 2 ibpa; c (solid black line): EIR decreasing from 20 down to 2 ibpa over 10 years; d (solid green line): EIR increasing after brief suppression from 2 to 20 ibpa over 10 years; e (solid orange line): EIR increasing from 2 to 20 ibpa after being suppressed for 10 years; f (solid purple line): EIR suppressed from 20 down to 2 ibpa, and subsequently maintained at 2 ibpa; g (dashed orange line): EIR = 20 ibpa.</p

Cumulative doses per capita, by delivery strategy, in a dynamic population.

<p>Legend: Black = EPI; Yellow = EPI plus catch-up of children up to 18 months of age; Brown = EPI plus school-based immunization of children 6–11 years of age; Green = Mass campaigns in entire population. The per capita estimates assume a dynamic population, modeled upon the age distribution in rural Tanzania.</p

Uncomplicated cases averted with RTS,S by transmission setting and delivery strategy.

<p><b>Legend</b>: The first column presents transmission settings. The second column presents the total estimated cases in the all-ages population of 100,000 people per person-year in the absence of vaccination. The estimate is the average over a 10 year period. The remaining columns present the percentage of cases averted by each delivery strategy, as the median and (range) estimated from 14 models.</p

Deaths averted with RTS,S by transmission setting and delivery strategy.

<p>Legend: The first column presents transmission settings. The second column presents the total estimated malaria deaths in the all-ages population of 100,000 people per person-year in the absence of vaccination. The estimate is the average over a 10 year period. The remaining columns present the percentage of deaths averted by each delivery strategy, as the median and (range) estimated from 14 models.</p

Summary of scenarios used in simulations.

<p><b>Legend</b>: EPI = Expanded Programme on Immunization; ibpa = infectious bites per annum.</p

Pooled Odds ratio for fetal loss after 2-3rd trimester exposures to artemisinins stratified by comparison group.

<p>*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ^McGready 1999 MQ or Q exposures include patients given MQ, Q, or both (33). ART: artesunate, AS-MQ: artesunate mefloquine, AL: artemether-lumefantrine, DP: dihydroartemisinin-piperaquine, AAP: artesunate atovaquone proguanil, AS-SP: artesunate sulfadoxine pyrimethamine, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+CQ: sulfadoxine pyrimethamine chloroquine, MQ: mefloquine, SP-AZM: sulfadoxine pyrimethamine azithromycin, CD: chlorproguanal-dapsone, IPT: intermittent preventative treatment, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.</p

Description of RCT studies identified in the systematic review and included in the meta-analysis.

<p>Description of RCT studies identified in the systematic review and included in the meta-analysis.</p

Pooled odds ratio for miscarriage after 2nd trimester exposures to artemisinins stratified by comparison group.

<p>*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis (12). ART artemisinins, AL artemether-lumefantrine, AS-SP artesunate sulfadoxine pyrimethamine, SP sulfadoxine pyrimethamine, No exp. No exposure to antimalarials.</p

PRISMA flow diagram for search results June 15, 2015.

<p>PRISMA flow diagram for search results June 15, 2015.</p

Pooled odds ratio for congenital anomalies after 2-3rd trimester exposures to artemisinins stratified by comparison group.

<p>*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ART: artesunate, AL: artemether-lumefantrine, AAP: artesunate- atovaquone proguanil, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+AQ: sulfadoxine pyrimethamine amodiaquine, MQ: mefloquine, CD: chlorproguanal-dapsone, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.</p